Deep Bio -- CORRECTION

Deep Bio is pleased to announce the availability of its CE-marked in-vitro diagnostic device, DeepDx Prostate, on the Swiss market. This strategic market expansion and product launch signify significant milestone in Deep Bio’s roadmap for expanding its footprint in Europe. The AI-powered Prostate Cancer Diagnostic Software enables pathologists to assess prostate cancer on digital whole slide images.

It automates the identification, grading, and quantification of cancerous lesions, helping reduce subjectivity and turnaround times. This diagnostic software empowers pathologists to make more accurate and efficient prostate cancer diagnoses, reducing subjectivity and turnaround times. It’s the first in Deep Bio’s suite of diagnostic software products that aim to enhance the diagnostic accuracy and optimize clinical management and patient outcomes.

“We are excited to introduce DeepDx Prostate to Switzerland,” said Sun Woo Kim, the CEO and founder of Deep Bio, “Increasing the reach of DeepDx Prostate to additional countries underscores Deep Bio’s unwavering commitment to improving global access to high-quality healthcare and advancing prostate cancer diagnosis through AI-driven innovation.” Deep Bio continues to expand its global reach through partnerships with several digital pathology leaders. The company also collaborates with leading US research institutions, including Stanford Medical School and Harvard Dana-Farber Cancer Institute, with its clinical validation studies published in prestigious medical journals.

Deep Bio Inc. is an AI healthcare company with expertise in deep learning and cancer pathology. The company aims to radically improve the efficiency and accuracy of pathologic cancer diagnosis and prognosis. The company’s AI software, DeepDx Prostate, is a clinically-validated AI for the assessment of prostate cancer that has been extensively tested at US CLIA labs. This AI software can alleviate the shortage of pathologists and reduce diagnostic subjectivity. To learn more, visit